

OPEN

Neural correlates of positive and negative symptoms through the illness course: an fMRI study in early psychosis and chronic schizophrenia

Lucy D. Vanes¹, Elias Mouchlianitis², Krisna Patel², Erica Barry³, Katie Wong², Megan Thomas², Timea Szentgyorgyi², Dan Joyce² & Sukhwinder Shergill²

Psychotic illness is associated with cognitive control deficits and abnormal recruitment of neural circuits subserving cognitive control. It is unclear to what extent this dysfunction underlies the development and/or maintenance of positive and negative symptoms typically observed in schizophrenia. In this study we compared fMRI activation on a standard Stroop task and its relationship with positive and negative symptoms in early psychosis (EP, N = 88) and chronic schizophrenia (CHR-SZ, N = 38) patients. CHR-SZ patients showed reduced frontal, striatal, and parietal activation across incongruent and congruent trials compared to EP patients. Higher positive symptom severity was associated with reduced activation across both trial types in supplementary motor area (SMA), middle temporal gyrus and cerebellum in EP, but not CHR-SZ patients. Higher negative symptom severity was associated with reduced cerebellar activation in EP, but not in CHR-SZ patients. A negative correlation between negative symptoms and activation in SMA and precentral gyrus was observed in EP patients and in CHR-SZ patients. The results suggest that the neural substrate of positive symptoms changes with illness chronicity, and that cognitive control related neural circuits may be most relevant in the initial development phase of positive symptoms. These findings also highlight a changing role for the cerebellum in the development and later maintenance of both positive and negative symptoms.

Deficits in executive functions are a core characteristic of psychotic disorders. Patients with psychosis typically display impaired performance on tasks involving executive functions such as cognitive control, working memory, planning, and cognitive flexibility^{1–3}. Abnormal cognitive control in particular has been proposed as a unifying theory of cognitive deficits in schizophrenia⁴ given its importance in a wider array of higher cognitive domains implicated in the illness, including episodic and working memory, flexible learning, task switching, response inhibition, and emotion regulation^{5–10}. Moreover, symptoms of psychosis can be understood in terms of concepts relevant to cognitive control, namely deficits in the flexible, adaptive control of thoughts and behaviour, as well as a difficulty in separating relevant from irrelevant environmental stimuli. Empirically, impaired behaviour on cognitive control tasks has been shown to correlate with symptoms of psychosis^{11–15}.

Functional imaging studies have demonstrated that cognitive control deficits in psychosis are accompanied by altered neural activation in relevant brain regions, including anterior cingulate cortex (ACC), supplementary motor area (SMA) and pre-SMA, superior and lateral prefrontal cortex (PFC), parietal cortex and aspects of the basal ganglia^{1,4,15–18}. It has been suggested that abnormal recruitment of these neural circuits, particularly in the context of cognitive control processes such as response inhibition, contributes to the presence of both positive^{15,19} and negative^{17,20} symptoms. However, several studies have found no relationship between abnormal activation

¹Wellcome Centre for Human Neuroimaging, University College London, 12 Queen Square, London, WC1N 3AR, United Kingdom. ²Institute of Psychiatry, Psychology and Neuroscience, de Crespigny Park, London, SE5 8AF, United Kingdom. ³Institute Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, NY, USA. Correspondence and requests for materials should be addressed to L.D.V. (email: lucy.vanes@ucl.ac.uk)

during response inhibition and symptoms^{21,22}, and thus the degree of specificity of the neural substrate of symptoms to cognitive control related processing remains unclear.

A further open question concerns the degree to which the neural underpinnings of symptoms in schizophrenia change over the course of the illness. It is possible that the mechanisms underlying the initial development of symptoms during the early phases of the illness differ from those in the later more chronic maintenance phase²³, and thus regions associated with psychotic symptoms are likely to vary through the course of the illness. Such a process may mirror habituation in the processing of perceptual stimuli or motor and cognitive learning, whereby a shift can be observed in the neural regions associated with early developmental and later more settled processing during the same task^{24,25}. Moreover, these neural mechanisms may become harder to identify as the illness progresses as they are increasingly subject to the confounding effects of illness chronicity, medication exposure, and socio-environmental deprivation; as well as any neuroplasticity related to persistence of these symptoms^{26,27}. For example, a correlation between disorganization symptoms and dorsolateral PFC activation has typically been observed during cognitive control tasks in drug-naïve schizophrenia patients²⁸, but was not observed in medicated patients^{17,21}. It has therefore been suggested that antipsychotic medication may alter the association between brain activity and symptoms²⁹. This has implications for studies attempting to pinpoint how symptoms develop; many fMRI studies include chronic patients with schizophrenia who have been medicated for a number of years.

A classic approach to identifying symptom-related brain activation is to clarify the regions showing abnormal activation in patients compared to healthy controls, and then to test for correlations with symptoms specifically within these regions²⁹. This method has the advantage of establishing a direct link between dysfunctional cognitive processing and clinical psychopathology. However, it relies on the presence of group differences in average activation, leading to a possible failure to identify associations in regions in which activation in patients does not differ from that in controls. Indeed, by its very nature, symptom heterogeneity can obscure group differences in average activation, such that etiologically relevant correlations between these symptom dimensions and neural activation patterns are not detected. This issue can be resolved by assessing associations between symptoms and neural activation on a whole-brain level independently of healthy control comparisons. The earliest studies took this approach with the use of resting state positron emission tomography (PET) by investigating associations between the severity of various symptom domains and regional cerebral blood flow (rCBF) in schizophrenia patients^{30–33} or by assessing the specificity of rCBF abnormalities to distinct symptom subgroups^{34–36}. Throughout the last two decades, the focus has shifted increasingly toward the use of task-related fMRI, although only few studies report the relationship between brain activation and symptom severity irrespective of activation differences relative to healthy control groups^{37–40}.

In the current study, we assess fMRI activation on a verbal Stroop task in a large sample of patients with early psychosis (EP) and a further sample of chronic patients with a diagnosis of schizophrenia (CHR-SZ). Previous studies have stressed the involvement of cognitive control in the development of both positive and negative symptoms; the role in maintenance of symptoms is less clear. Thus, we hypothesise an association between symptoms and activation in cognitive control related regions such as ACC and SMA/pre-SMA in EP patients rather than chronic patients. In an exploratory approach, we compare correlations between activation and symptoms between EP and CHR-SZ groups to address the question of changes in the neural substrate of symptoms throughout the course of illness. If cognitive control related mechanisms are primarily involved in the development, but not maintenance, of symptoms, correlations will no longer be observed in the chronic patient group. We analyse both activation that is specific to response inhibition (incongruent vs. congruent condition) as well as activation averaged across both task conditions, reflecting the more general effects of cognitive control and attentional processing.

Method

Participants. Ninety-five medicated early psychosis (EP) patients participated in the study. Inclusion criteria required patients to have experienced a first episode of psychosis within the previous five years, however the mean duration of illness was 1.7 years. In addition, 38 medicated chronic schizophrenia patients (CHR-SZ) were included (mean duration of illness 15.7 years). The CHR-SZ group consisted of treatment resistant and treatment responsive patients (matched for key demographic and clinical variables and thus relatively homogeneous aside from symptom severity) who were previously shown not to differ on the Stroop task⁴¹ and were thus collapsed into one group. Exclusion criteria for all patients were a history of neurological illness, current major physical illness, and drug dependency over the last six months. Positive and negative symptom severity was assessed by a trained researcher using the Positive and Negative Syndrome Scale (PANSS)⁴². Sample characteristics are presented in Table 1. All subjects provided written informed consent to take part the study and were compensated for their time and travel. The London Camberwell St Giles Research provided ethical approval and Ethics Committee and experiments were compliant with the Declaration of Helsinki.

Procedure. Subjects performed a verbal Stroop paradigm while undergoing functional magnetic resonance imaging. A description of the task as well as imaging procedures and processing can be found in the Supplementary Materials.

Behavioural data analysis. While behavioural performance was monitored during completion of the task to ensure that participants had understood the task instructions and were not responding randomly, reliable reaction times (RTs) from a number of trials could not be extracted from resulting audio files due to technical issues for some participants. Participants for whom RT data from more than 20 trials were unavailable were excluded from the behavioural analysis, resulting in a behavioural sample of 75 EP and 36 CHR-SZ patients. The reaction time (RT) Stroop effect (defined as mean RT in milliseconds on incongruent minus mean RT in milliseconds

	EP		CHR-SZ		<i>T</i>	<i>P</i>
	<i>M</i>	<i>SD</i>	<i>M</i>	<i>SD</i>		
Age	26.5	6.1	42.7	10.0	9.27	<0.001
WASI IQ	98.8	16.2	94.7	16.1	1.29	0.201
Onset age (years)	24.9	6.2	26.8	6.6	1.55	0.122
Illness duration (years)	1.7	1.3	15.6	9.4	9.02	<0.001
CPZ equivalents	244.0	144.1	367.0	222.7	3.13	0.002
PANSS score						
Positive symptoms	13.5	5.6	15.7	5.7	1.93	0.060
Negative symptoms	13.3	5.5	16.2	6.2	2.56	0.012
General symptoms	30.0	8.0	29.4	9.7	0.41	0.684
Total score	56.9	16.3	61.7	18.9	1.45	0.149
					χ^2	<i>P</i>
Female (%)	15		42		3.01	0.083

Table 1. Sample characteristics of the early psychosis (EP) and chronic schizophrenia (CHR-SZ) patient groups.

on congruent trials) as well as the Accuracy Stroop effect (defined as accuracy on congruent minus accuracy on incongruent trials) was assessed for each subject and compared between groups using *t*-tests.

Imaging data analysis. Three EP subjects were excluded due to technical problems with the neuroimaging data, and a further four EP patients were excluded due to the absence of PANSS data, resulting in a final MRI sample of 88 EP and 38 CHR-SZ patients. The functional MRI data were analysed using the general linear model as implemented in FSL FEAT. For the first level analysis, regressors representing onsets of stimulus presentation for incongruent trials and congruent trials were included into the model. Each regressor was modelled as a delta function and convolved with a canonical hemodynamic response function. Standard and extended motion parameters, as well as a motion artefact confound matrix, which identified motion-corrupted volumes, were added as regressors of no interest. Volumes detected as corrupted were calculated by DVARS⁴³ as implemented by FSL Motion Outliers. Contrasts of interest for the group level analysis were the *Stroop* contrast (Incongruent > Congruent) and the *Task* contrast (Incongruent + Congruent). Whole-brain activation was determined by a voxelwise *z*-threshold of 3.1 ($p < 0.001$ uncorrected) and a cluster significance threshold of $p = 0.05$ (whole-brain FWE corrected for multiple comparisons).

We examined significant activation across both groups as well as group differences in activation for both of these contrasts. Correlations between brain activation and symptoms were initially assessed within each group separately. This was done in order to increase power to detect group-specific associations between symptoms and brain activation. Next, group \times symptom interactions were assessed on a whole-brain level as well as within regions of interest (ROIs) defined by the significant group-specific correlation clusters. The ROI approach was taken in order to avoid false interpretations about group differences in correlations (since the presence of an association in one group in the absence of that association in the other group does not automatically amount to a significant difference in the association between groups). Due to a significant group difference in chlorpromazine (CPZ) equivalent dosage and a marginally significant difference in sex distributions between the two groups, we tested whether regional effects from the group comparison analyses remained significant after controlling for CPZ equivalent dose and sex to exclude the possibility that findings were due to these possible confounds.

Results

Symptoms. The severity of positive and negative symptoms was somewhat higher in the CHR-SZ group compared to the EP group (Table 1), however this only reached significance in negative symptoms. There was no difference in total PANSS scores between the two groups. Importantly, both patient groups showed a similar range of PANSS positive (EP: min = 7, max = 35; CHR-SZ: min = 7, max = 26) and negative (EP: min = 7, max = 30; CHR-SZ: min = 7, max = 29) scores, indicating that correlative analyses within each group would cover a similar range of symptom severity. Mean symptom severity as well as frequency distributions of the individual positive and negative symptom subscales for each group are depicted in Supplementary Figs 2–5, indicating overall comparable symptom profiles in the two groups.

Behavioural results. Behavioural data analyses were conducted on 75 EP and 36 CHR-SZ patients. A significant RT Stroop effect was observed both in EP ($M = 141.70$, $SD = 105.05$, $p < 0.001$) and in CHR-SZ ($M = 179.78$, $SD = 133.88$, $p < 0.001$) patients, but this did not differ between groups, $p = 0.14$. There was also a significant Accuracy Stroop effect in EP ($M = 0.05$, $SD = 0.07$, $p < 0.001$) and CHR-SZ ($M = 0.07$, $SD = 0.08$, $p < 0.001$) patients, which did not differ significantly between groups, $p = 0.17$.

Neuroimaging results. *Mean activation.* MRI analyses were conducted on 88 EP and 38 CHR-SZ patients.

On the *Stroop* (incongruent > congruent) contrast, significant activation was observed across both groups in regions classically associated with the Stroop task, including a midline section extending from ACC to supplementary motor area (SMA), bilateral precentral cortices, bilateral striatum and thalamus, and intracalcarine




Figure 1. Main effect of group for the Task (incongruent + congruent) contrast, with peak activation in right superior parietal cortex [16, -54, 56], left middle frontal gyrus [-40, -6, 52], and left putamen [-22, 16, -2].

cortex. Significant deactivation was observed in right lateral occipital cortex (see Supplementary Fig. 1A). Exact regions can be found in Supplementary Table 1.

On the *Task* (incongruent + congruent) contrast, there was more widespread activation in areas including ACC/SMA and bilateral prefrontal cortical regions extending to precentral gyri, bilateral thalamus, putamen, brainstem, superior parietal cortices and cerebellum. Significant deactivations were observed in medial prefrontal cortex, bilateral superior frontal cortex, temporal poles, precuneus and lateral occipital cortices (see Supplementary Fig. 1B). These regions of deactivation are mostly consistent with areas associated with the default mode network, which is known to deactivate during task engagement. All significant regions of activation and deactivation are listed in Supplementary Table 2.

Group differences in activation. One-way analysis of variance did not reveal any differences in activation between EP and CHR-SZ patients for the *Stroop* contrast. However, there was a significant effect of group on the *Task* contrast in several regions. Specifically, across both trial conditions, EP showed greater activation than CHR-SZ in right superior parietal cortex (MNI: 16, -54, 56; 1197 voxels; $p < 0.001$), left middle frontal gyrus (MNI: -40, -6, 52; 330 voxels, $p = 0.004$), and left putamen (MNI: -22, 16, -2; 292 voxels; $p = 0.007$) (Fig. 1). Interestingly, this was due to significant activation in EP in all three regions, but deactivation in CHR-SZ in superior parietal cortex and putamen, and no significant activation in middle frontal gyrus. Group differences in these regions remained significant after controlling for CPZ equivalents and sex, all $ps < 0.001$.

Correlations with symptoms. There were no significant correlations between *Stroop* activation and either positive or negative symptoms in the EP or CHR-SZ patient group, nor was there a significant group \times (positive or negative) symptom interaction at whole-brain level.

On the *Task* contrast, EP patients showed a significant negative correlation between activation and positive symptoms in a midline precentral gyrus region including the dorsal SMA as well as left middle temporal gyrus (Fig. 2). Higher symptom severity was associated with reduced neural activation across both incongruent and congruent conditions in these regions.

EP patients also showed a significant negative correlation between activation on the *Task* contrast and negative symptoms in dorsal SMA, right precentral gyrus, and cerebellum (Fig. 3). Again, higher symptom severity was associated with reduced activation in these regions across both task conditions.

No significant correlations between neural activation and (positive or negative) symptom severity were observed for the *Task* contrast in CHR-SZ patients.

A whole-brain analysis of the Group \times positive symptom interaction on the *Task* contrast revealed a significant effect in a cluster extending from the cerebellum to lingual gyrus (MNI: 10, -46, -10; 770 voxels; $p < 0.001$) (Fig. 4). In this region, EP patients showed a negative correlation between positive symptoms and activation, whereas CHR-SZ patients showed a positive correlation. The interaction in this region remained significant after controlling for CPZ equivalent medication dose and sex, $p < 0.001$.

Next we tested for Group \times symptom interactions in the significant correlation clusters observed in the EP group, in order to ascertain whether correlations in these regions specifically were significantly different in the CHR-SZ group. For positive symptoms, there was a significant interaction both in the midline precentral region including the dorsal SMA (beta = 176.26, $p = 0.026$), as well as the middle temporal gyrus region (beta = 231.68,




Figure 2. Correlation between positive symptoms and Task (incongruent + congruent) activation in early psychosis patients, with peak activation in precentral gyrus including dorsal supplementary motor area [2, -28, 62] and left middle temporal gyrus [-46, -62, 8].




Figure 3. Correlation between negative symptoms and Task (incongruent + congruent) activation in early psychosis patients, with peak activation in the supplementary motor area [12, -12, 58], right precentral gyrus [30, -8, 56], and cerebellum [-6, -62, -40].

$p = 0.009$), indicating that the correlation between positive symptoms and neural activation differed significantly between groups. While EP showed a negative correlation between symptoms and activation in these regions (precentral gyrus/SMA: $R = -0.40$, $p < 0.001$; middle temporal gyrus: $R = -0.39$, $p < 0.001$), a non-significant positive correlation was observed in CHR-SZ patients (precentral: $R = 0.03$, $p = 0.872$; middle temporal gyrus: $R = 0.12$, $p = 0.493$). The interaction terms in these regions remained significant after controlling for CPZ equivalent medication dose and sex, all $ps < 0.05$. For negative symptoms, a significant interaction was only observed in the cerebellar cluster (beta = 226.14, $p = 0.004$). Again, while there was a negative correlation in the EP group




Figure 4. Group \times positive symptom interaction for the Task (incongruent + congruent) contrast, with peak activation in the cerebellum [10, -46, -10].

($R = -0.47$, $p < 0.001$), there was a non-significant correlation in the CHR-SZ group ($R = 0.09$, $p = 0.600$). The interaction in this region remained significant after controlling for CPZ equivalent medication dose and sex, $p < 0.05$. In contrast, no significant group \times negative symptom interaction was observed in the SMA or precentral gyrus, indicating that the negative correlations between negative symptom severity and activation in these regions did not differ significantly between EP (SMA: $R = -0.42$, $p < 0.001$; precentral gyrus: $R = -0.45$, $p < 0.001$) and CHR-SZ patients (SMA: $R = -0.14$, $p = 0.401$; precentral gyrus: $R = -0.09$, $p = 0.622$).

Discussion

In this study, we assessed whole-brain activation on a Stroop task and correlations with symptom severity in a large sample of early psychosis (EP) patients compared to a sample of chronic schizophrenia (CHR-SZ) patients. Subjects showed overall activation in regions consistent with a cognitive control network including ACC, SMA, bilateral motor cortices, thalamus and striatum. The key finding of this study is a differential correlation between positive symptom severity and activation in SMA, middle temporal gyrus and cerebellum in EP and CHR-SZ patients, as well as between negative symptom severity and activation in the cerebellum in the two groups. Activation was inversely related to symptom severity in EP patients, but was not related to symptoms in chronic patients, with the exception of cerebellar activation, which showed a positive correlation with positive symptoms in CHR-SZ. These results suggest that the extent to which cognitive control related mechanisms are associated with symptoms differs as a function of illness chronicity, as is discussed in more detail below.

In the between-group comparison of activation, chronic patients showed reduced overall task activation across both trial types compared to EP patients in left middle frontal gyrus, right superior parietal cortex and left putamen, regions known to be important in cognitive control⁴⁴. The findings suggest that activity in this functional network may decrease over the illness course, consistent with previous findings that Stroop-related activation is negatively related to number of psychotic episodes experienced⁴⁵.

We observed a significant association between positive symptom severity and reduced activation in medial precentral gyrus including the dorsal SMA and left posterior middle temporal gyrus in EP. The left middle temporal gyrus is relevant for semantic control during language generation^{46,47} and is also known to be involved in resolution of semantic interference during overt responding⁴⁸. Recent research suggests that similar mechanisms underlie semantic interference effects and classic Stroop colour-word interference⁴⁹. Additionally, left middle temporal gyrus has been repeatedly implicated in schizophrenia, with reduced volume observed compared to healthy controls in chronic schizophrenia patients as well as first episode psychosis patients and their unaffected siblings⁵⁰⁻⁵². Middle temporal gyrus activation has been observed during auditory hallucinations^{53,54} and functional as well as structural abnormalities have been associated with the severity of hallucinatory symptoms^{50,55}. Activation of medial sensorimotor and premotor cortices is commonly observed in the Stroop task and is likely involved in error monitoring when exerting cognitive control⁵⁶. Interestingly, SMA dysfunction has also been associated with alien limb syndrome, whereby movements are experienced as occurring independently of an individual's own active control^{57,58}. This is suggested to result from an inability to suppress implicitly activated motor programmes, normally controlled by SMA regions⁵⁹. The resulting failure to distinguish internally and externally

generated movement is akin to delusions of control commonly observed in psychosis. Our findings suggest that abnormal functioning of the SMA and middle temporal regions in the context of cognitive control may provide an important marker of positive symptom severity during the development stage rather than chronic stage of psychotic illness. We did not observe a correlation between symptoms and the region most classically associated with cognitive control, the anterior cingulate cortex (ACC). This relates to a meta-analytic review of neural activation during executive function tasks in schizophrenia, which showed abnormal ACC activation in patients across all tasks, but more dorsal effects closer to the SMA for the Stroop task specifically¹.

With respect to negative symptoms, we observed an inverse relationship with activation in SMA, right precentral gyrus and cerebellum in EP. Similar to the correlations with positive symptoms, this association indicates that EP patients with severe negative symptoms are less able to recruit these regions while exerting cognitive control. Negative symptoms have long been associated with cognitive dysfunction in schizophrenia⁶⁰ and several authors have emphasised the role of diminished cognitive control in the failure to learn reward outcomes, ultimately leading to motivational subcomponents of negative symptomatology such as anhedonia and avolition^{61,62}. Interestingly, the correlation in SMA and precentral gyrus did not differ significantly from that in chronic patients, suggesting that the cortical neural substrate of negative symptoms remains more stable over the illness course, in contrast to that of positive symptoms.

A striking finding in this study is that of reduced cerebellar activation with increasing (positive and negative) symptom severity in EP patients, but increased cerebellar activation with more severe symptoms in the CHR-SZ group. The traditional, limited view of the cerebellum as being primarily involved in motor or associative learning has been revised in recent decades with the accumulation of evidence showing that the cerebellum is involved in a multitude of higher cognitive processes^{63,64}. There is an increasing consensus that the cerebellum acts as a coordinator or modulator of cortical activity via a cortico-cerebellar-thalamo-cortical circuit (CCTCC). CCTCC dysfunction in schizophrenia, driven or contributed to by cerebellar abnormalities, has been suggested to result in poorly coordinated mental activity (“cognitive dysmetria”), which may underlie a range of symptoms and cognitive abnormalities^{65,66}. Underscoring a potential causal role of the cerebellum in symptom development, several recent interventional studies have shown that application of repetitive transcranial magnetic stimulation to the cerebellar vermis results in a significant improvement of negative symptom severity in patients with schizophrenia^{67–69}.

Our findings suggest that the role of the cerebellum with respect to symptoms differs in the early and late stages of psychosis. The observation is partly mirrored in findings from previous PET research showing a positive correlation between cerebellar rCBF and both positive and negative symptoms in chronic schizophrenia patients⁷⁰, but a negative correlation with negative symptoms observed in neuroleptic-naïve first episode psychosis (FEP) patients by the same group⁷¹. Increased cerebellar activation in conjunction with increased symptom severity was interpreted by the authors as compensatory activity in response to decreases in other regions of the CCTCC. This interpretation is in line with reduced cortical and subcortical activation observed in our study in chronic patients compared to EP patients with relatively preserved task performance. Both hyper- and hypoactivations of the cerebellum have been observed in schizophrenia on a range of tasks including working memory and affective processing^{72–74}, providing further support for a dynamically changing role of the cerebellum in psychosis.

It is important to highlight that all neuroimaging effects observed in this study relate to the *Task* contrast, which averages over both incongruent and congruent trials. Thus, the observed activation changes associated with this contrast are not specific to response inhibition; however they likely nevertheless reflect effects of cognitive or attentional control more generally. As can be seen in Supplementary Fig. 1, activation associated with the *Task* contrast is highly similar to that associated with the *Stroop* contrast, with some additional activation in parietal, occipital and cerebellar regions. While it is reasonable to assume that the *Stroop* contrast taps into response conflict specifically, it is clear that congruent trials are not free from cognitive control (particularly in task setups with randomly interspersed trial types) and as such subtracting these out may obscure effects relevant for control related processes⁷⁵.

A limitation of this study is the unequal sample sizes of the EP and CHR-SZ groups. It is possible that the EP sample was more sensitive to correlation effects due to a larger number of participants. However, the CHR-SZ consisted of a reasonably large sample of 38 patients, providing over 80% power to detect a comparable correlation of 0.4 as observed in the EP sample. We are therefore confident that our analyses did not miss a clinically meaningful true correlation between brain activation and symptom severity. In this study we cannot rule out a potential treatment effect caused by long-term medication exposure in the chronic patient group, who were also receiving a higher dosage of antipsychotic medication at the time of study. This is a common limitation inherent to research in chronic medicated patients, further emphasising the importance of studying neural correlates of symptoms early on in the illness. However, controlling for current medication dosage did not significantly alter the observed group differences, suggesting that this unlikely confounded our findings. A related issue pertains to the heterogeneity of the studied samples. The chronic cohort consisted of patients with a diagnosis of schizophrenia who had responded to antipsychotic treatment to variable extents. The early psychosis cohort, in contrast, were early on in their illness trajectory, and it is possible that a number of these patients will not go on to receive a diagnosis of schizophrenia. Future research will benefit from within-subject longitudinal follow-up designs in order to address the role of illness chronicity in the brain-symptom relationship more reliably. Finally, given the correlative nature of fMRI, it is not possible to infer a definitive causal relationship between cognitive control related neural mechanisms and symptom development. However, understanding the spatial distribution of the neural correlates of symptoms can provide insights into potential associated mechanisms and thereby offer a basis for future causal investigations such as non-invasive intervention studies. Future research could also usefully examine changes in functional connectivity beyond simple activation in order to establish whether a breakdown of network connectivity is involved in symptom development and maintenance.

Overall the results of this study suggest that positive symptoms are associated with abnormalities in cognitive control related circuits in the early stages of psychosis, but once stabilised are no longer tightly coupled with mechanisms underlying cognitive control. In contrast, the cortical neural substrate of negative symptoms appears to remain more stable over the psychotic illness course. Finally, the findings suggest that initial formation and later maintenance of positive and negative symptoms may be associated with opposite mechanisms in the cerebellum. These results bear implications not only for the mechanistic understanding of symptoms but also research into potential targets for novel treatments, since different mechanisms may need to be targeted depending on the stage of psychotic illness.

Data and Code Availability

Data and code are available from the corresponding author upon reasonable request.

References

1. Minzenberg, M. J., Laird, A. R., Thelen, S., Carter, C. S. & Glahn, D. C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. *Arch. Gen. Psychiatry* **66**, 811–822 (2009).
2. Eisenberg, D. P. & Berman, K. F. Executive function, neural circuitry, and genetic mechanisms in schizophrenia. *Neuropsychopharmacology* **35**, 258–277 (2010).
3. Knowles, E. E. *et al.* The puzzle of processing speed, memory, and executive function impairments in schizophrenia: Fitting the pieces together. *Biol. Psychiatry* **78**, 786–793 (2015).
4. Lesh, T. A., Niendam, T. A., Minzenberg, M. J. & Carter, C. S. Cognitive control deficits in schizophrenia: mechanisms and meaning. *Neuropsychopharmacology* **36**, 316 (2011).
5. Cohen, J. D. & Braver, T. S. A computational approach to prefrontal cortex, cognitive control and schizophrenia: recent developments and current challenges. *Phil. Trans. R. Soc. Lond. B* **351**, 1515–1527 (1996).
6. Banich, M. T. *et al.* Prefrontal regions play a predominant role in imposing an attentional ‘set’: evidence from fMRI. *Cognitive Brain Research* **10**, 1–9 (2000).
7. Ochsner, K. N. & Gross, J. J. The cognitive control of emotion. *Trends in cognitive sciences* **9**, 242–249 (2005).
8. Ragland, J. D. *et al.* Prefrontal activation deficits during episodic memory in schizophrenia. *Am. J. Psychiatry* **166**, 863–874 (2009).
9. Ranganath, C., Minzenberg, M. J. & Ragland, J. D. The cognitive neuroscience of memory function and dysfunction in schizophrenia. *Biol. Psychiatry* **64**, 18–25 (2008).
10. Vanes, L. D., Mouchlianitis, E., Collier, T., Averbach, B. B. & Shergill, S. S. Differential neural reward mechanisms in treatment-responsive and treatment-resistant schizophrenia. *Psychol. Med.*, 1–10 (2018).
11. Barch, D. M., Carter, C. S., MacDonald, A. W. III., Braver, T. S. & Cohen, J. D. Context-processing deficits in schizophrenia: diagnostic specificity, 4-week course, and relationships to clinical symptoms. *J. Abnorm. Psychol.* **112**, 132 (2003).
12. Cohen, J. D., Barch, D. M., Carter, C. & Servan-Schreiber, D. Context-processing deficits in schizophrenia: converging evidence from three theoretically motivated cognitive tasks. *J. Abnorm. Psychol.* **108**, 120 (1999).
13. Barch, D. M., Carter, C. S., Hachten, P. C., Usher, M. & Cohen, J. D. The “benefits” of distractibility: mechanisms underlying increased Stroop effects in schizophrenia. *Schizophr. Bull.* **25**, 749 (1999).
14. Woodward, T. S., Ruff, C. C., Thornton, A. E., Moritz, S. & Liddle, P. F. Methodological considerations regarding the association of Stroop and verbal fluency performance with the symptoms of schizophrenia. *Schizophr. Res.* **61**, 207–214 (2003).
15. Yoon, J. H. *et al.* Association of dorsolateral prefrontal cortex dysfunction with disrupted coordinated brain activity in schizophrenia: relationship with impaired cognition, behavioral disorganization, and global function. *Am. J. Psychiatry* **165**, 1006–1014 (2008).
16. Barch, D. M. *et al.* Selective deficits in prefrontal cortex function in medication-naïve patients with schizophrenia. *Arch. Gen. Psychiatry* **58**, 280–288 (2001).
17. Snitz, B. E. *et al.* Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naïve state and effects of short-term atypical antipsychotic treatment. *Am. J. Psychiatry* **162**, 2322–2329 (2005).
18. Sutcliffe, G., Harneit, A., Tost, H. & Meyer-Lindenberg, A. Neuroimaging intermediate phenotypes of executive control dysfunction in schizophrenia. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging* **1**, 218–229 (2016).
19. Perlstein, W. M., Carter, C. S., Noll, D. C. & Cohen, J. D. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. *Am. J. Psychiatry* **158**, 1105–1113 (2001).
20. Edwards, B. G., Barch, D. M. & Braver, T. S. Improving prefrontal cortex function in schizophrenia through focused training of cognitive control. *Front. Hum. Neurosci.* **4**, 32 (2010).
21. MacDonald, A. W. III. & Carter, C. S. Event-related fMRI study of context processing in dorsolateral prefrontal cortex of patients with schizophrenia. *J. Abnorm. Psychol.* **112**, 689 (2003).
22. Arce, E. *et al.* Individuals with schizophrenia present hypo- and hyperactivation during implicit cueing in an inhibitory task. *Neuroimage* **32**, 704–713 (2006).
23. Pantelis, C. *et al.* Neurobiological markers of illness onset in psychosis and schizophrenia: the search for a moving target. *Neuropsychol. Rev.* **19**, 385 (2009).
24. Doyon, J., Penhune, V. & Ungerleider, L. G. Distinct contribution of the cortico-striatal and cortico-cerebellar systems to motor skill learning. *Neuropsychologia* **41**, 252–262 (2003).
25. Beauchamp, M., Dagher, A., Aston, J. & Doyon, J. Dynamic functional changes associated with cognitive skill learning of an adapted version of the Tower of London task. *Neuroimage* **20**, 1649–1660 (2003).
26. Shergill, S. S. *et al.* A diffusion tensor imaging study of fasciculi in schizophrenia. *The American journal of psychiatry* **164**, 467–473 (2007).
27. Hubl, D. *et al.* Pathways that make voices: white matter changes in auditory hallucinations. *Arch. Gen. Psychiatry* **61**, 658–668 (2004).
28. MacDonald, A. W. III. *et al.* Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. *Am. J. Psychiatry* **162**, 475–484 (2005).
29. Goghari, V. M., Sponheim, S. R. & MacDonald, A. W. III. The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. *Neurosci. Biobehav. Rev.* **34**, 468–486 (2010).
30. Sabri, O., Erkwow, R., Schreckenberger, M. & Cremerius, U. Regional cerebral blood flow and negative/positive symptoms in 24 drug-naïve schizophrenics. *The Journal of Nuclear Medicine* **38**, 181 (1997).
31. Sabri, O. *et al.* Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. *The Lancet* **349**, 1735–1739 (1997).
32. Franck, N., O’Leary, D. S., Flaum, M., Hichwa, R. D. & Andreasen, N. C. Cerebral blood flow changes associated with Schneiderian first-rank symptoms in schizophrenia. *The Journal of neuropsychiatry and clinical neurosciences* **14**, 277–282 (2002).
33. Lahti, A. C. *et al.* Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. *Neuropsychopharmacology* **31**, 221 (2006).
34. Liddle, P., Friston, K., Frith, C. & Frackowiak, R. Cerebral blood flow and mental processes in schizophrenia. *J. R. Soc. Med.* **85**, 224 (1992).

35. Dolan, R. *et al.* Dorsolateral prefrontal cortex dysfunction in the major psychoses: symptom or disease specificity? *J. Neurol. Neurosurg. Psychiatry* **56**, 1290–1294 (1993).
36. Yuasa, S. *et al.* Clinical symptoms and regional cerebral blood flow in schizophrenia. *Eur. Arch. Psychiatry Clin. Neurosci.* **246**, 7–12 (1995).
37. Whalley, H. C. *et al.* Correlations between fMRI activation and individual psychotic symptoms in un-medicated subjects at high genetic risk of schizophrenia. *BMC Psychiatry* **7**, 61 (2007).
38. Nishimura, Y. *et al.* Prefrontal cortex activity during response inhibition associated with excitement symptoms in schizophrenia. *Brain Res.* **1370**, 194–203 (2011).
39. Schnell, K. *et al.* Correlation of passivity symptoms and dysfunctional visuomotor action monitoring in psychosis. *Brain*, 2783–2797 (2008).
40. Shaffer, J. J. *et al.* Neural correlates of schizophrenia negative symptoms: distinct subtypes impact dissociable brain circuits. *Molecular neuropsychiatry* **1**, 191–200 (2015).
41. Vanes, L. D., Mouchlianitis, E., Wood, T. C. & Shergill, S. S. J. N. C. White matter changes in treatment refractory schizophrenia: Does cognitive control and myelination matter? *NeuroImage: Clinical* **18**, 186–191, <https://doi.org/10.1016/j.nicl.2018.01.010> (2018).
42. Kay, S. R., Fiszbein, A. & Opfer, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr. Bull.* **13**, 261 (1987).
43. Power, J. D., Barnes, K. A., Snyder, A. Z., Schlaggar, B. L. & Petersen, S. E. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. *Neuroimage* **59**, 2142–2154 (2012).
44. Niendam, T. A. *et al.* Meta-analytic evidence for a superordinate cognitive control network subserving diverse executive functions. *Cognitive, Affective, & Behavioral Neuroscience* **12**, 241–268 (2012).
45. Jeong, B. S. *et al.* Functional imaging evidence of the relationship between recurrent psychotic episodes and neurodegenerative course in schizophrenia. *Psychiatry Research: Neuroimaging* **139**, 219–228 (2005).
46. Indefrey, P. & Levelt, W. J. In *The new cognitive neurosciences; 2nd ed.* 845–865 (MIT press, 2000).
47. Whitney, C., Kirk, M., O’Sullivan, J., Lambon Ralph, M. A. & Jefferies, E. The neural organization of semantic control: TMS evidence for a distributed network in left inferior frontal and posterior middle temporal gyrus. *Cereb. Cortex* **21**, 1066–1075 (2010).
48. de Zubicaray, G. I., Wilson, S. J., McMahon, K. L. & Muthiah, S. The semantic interference effect in the picture-word paradigm: An event-related fMRI study employing overt responses. *Hum. Brain Mapp.* **14**, 218–227 (2001).
49. Starreveld, P. A. & La Heij, W. Picture-word interference is a Stroop effect: A theoretical analysis and new empirical findings. *Psychonomic bulletin & review* **24**, 721–733 (2017).
50. Onitsuka, T. *et al.* Middle and inferior temporal gyrus gray matter volume abnormalities in chronic schizophrenia: an MRI study. *Am. J. Psychiatry* **161**, 1603–1611 (2004).
51. Hu, M. *et al.* Decreased left middle temporal gyrus volume in antipsychotic drug-naive, first-episode schizophrenia patients and their healthy unaffected siblings. *Schizophr. Res.* **144**, 37–42 (2013).
52. Lennox, B. R., Park, S. B. G., Medley, I., Morris, P. G. & Jones, P. B. The functional anatomy of auditory hallucinations in schizophrenia. *Psychiatry Research: Neuroimaging* **100**, 13–20 (2000).
53. Shergill, S. S., Brammer, M. J., Williams, S. C., Murray, R. M. & McGuire, P. K. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. *Arch. Gen. Psychiatry* **57**, 1033–1038 (2000).
54. Lennox, B. R., Bert, S., Park, G., Jones, P. B. & Morris, P. G. Spatial and temporal mapping of neural activity associated with auditory hallucinations. *The Lancet* **353**, 644 (1999).
55. McGuire, P., Silbersweig, D. & Wright, I. Abnormal monitoring of inner speech: A physiological basis for auditory hallucinations. *Year Book of Psychiatry and Applied Mental Health* **1997**, 407–408 (1997).
56. Ridderinkhof, K. R., Ullsperger, M., Crone, E. A. & Nieuwenhuis, S. The role of the medial frontal cortex in cognitive control. *Science* **306**, 443–447 (2004).
57. Feinberg, T. E., Schindler, R. J., Flanagan, N. G. & Haber, L. D. Two alien hand syndromes. *Neurology* **42**, 19–19 (1992).
58. Della Sala, S., Marchetti, C. & Spinnler, H. Right-sided anarchic (alien) hand: a longitudinal study. *Neuropsychologia* **29**, 1113–1127 (1991).
59. Nachev, P., Kennard, C. & Husain, M. Functional role of the supplementary and pre-supplementary motor areas. *Nature Reviews Neuroscience* **9**, 856 (2008).
60. Millan, M. J., Fone, K., Steckler, T. & Horan, W. P. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. *Eur. Neuropsychopharmacol.* **24**, 645–692 (2014).
61. Kring, A. M. & Barch, D. M. The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs. *Eur. Neuropsychopharmacol.* **24**, 725–736 (2014).
62. Barnes, S. A., Der-Avakian, A. & Markou, A. Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. *Eur. Neuropsychopharmacol.* **24**, 744–758 (2014).
63. Schmahmann, J. D. An emerging concept: the cerebellar contribution to higher function. *Arch. Neurol.* **48**, 1178–1187 (1991).
64. Buckner, R. L. The cerebellum and cognitive function: 25 years of insight from anatomy and neuroimaging. *Neuron* **80**, 807–815 (2013).
65. Andreasen, N. C. & Pierson, R. The role of the cerebellum in schizophrenia. *Biol. Psychiatry* **64**, 81–88 (2008).
66. Picard, H., Amado, I., Mouchet-Mages, S., Olié, J.-P. & Krebs, M.-O. The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences. *Schizophr. Bull.* **34**, 155–172 (2007).
67. Garg, S., Sinha, V. K., Tikka, S. K., Mishra, P. & Goyal, N. J. P. R. The efficacy of cerebellar vermal deep high frequency (theta range) repetitive transcranial magnetic stimulation (rTMS) in schizophrenia: a randomized rater blind-sham controlled study. **243**, 413–420 (2016).
68. Brady, R. O. Jr. *et al.* Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia. *appi. ajp.* 2018.18040429 (2019).
69. Demirtas-Tatlidede, A. *et al.* Safety and proof of principle study of cerebellar vermal theta burst stimulation in refractory schizophrenia. **124**, 91–100 (2010).
70. Kim, J.-J. *et al.* Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography. *Am. J. Psychiatry* **157**, 542–548 (2000).
71. Andreasen, N. C. *et al.* Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. *The Lancet* **349**, 1730–1734 (1997).
72. Mendrek, A. *et al.* Dysfunction of a distributed neural circuitry in schizophrenia patients during a working-memory performance. *Psychol. Med.* **35**, 187–196 (2005).
73. Stip, E. *et al.* Neural correlates of sad feelings in schizophrenia with and without blunted affect. *The Canadian Journal of Psychiatry* **50**, 909–917 (2005).
74. Takahashi, H. *et al.* An fMRI study of differential neural response to affective pictures in schizophrenia. *Neuroimage* **22**, 1247–1254 (2004).
75. Milham, M. P. *et al.* Attentional control in the aging brain: insights from an fMRI study of the stroop task. *Brain Cogn.* **49**, 277–296 (2002).

Acknowledgements

We thank the radiographic team at the Centre for Neuroimaging Sciences for their support, and Felix Dransfield, Christiana Ilesanmi, Valentina Forassi and Juliet Gillam for assistance with fMRI scanning and behavioural testing. This research was funded by a European Research Council Grant to SSS (Grant Number 311686), and developed by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and a joint infrastructure grant from Guy's and St Thomas' Charity and the Maudsley Charity.

Author Contributions

L.D.V. study design, data analysis and manuscript preparation; E.M. and D.J. study design and revision of manuscript; E.B., K.P., K.W., M.T. and T.S. data collection and revision of manuscript; S.S. conception and funding.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-51023-0>.

Competing Interests: The authors declare no competing interests.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019